The latest price target for Aldeyra Therapeutics (NASDAQ:ALDX) was reported by BTIG on November 10, 2025. The analyst firm set a price target for $9.00 expecting ALDX to rise to within 12 months (a possible 72.08% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Aldeyra Therapeutics (NASDAQ:ALDX) was provided by BTIG, and Aldeyra Therapeutics reiterated their buy rating.

The last upgrade for Aldeyra Therapeutics Inc happened on April 3, 2024 when Oppenheimer raised their price target to $10. Oppenheimer previously had a perform for Aldeyra Therapeutics Inc.

The last downgrade for Aldeyra Therapeutics Inc happened on October 17, 2023 when Oppenheimer changed their price target from N/A to N/A for Aldeyra Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aldeyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aldeyra Therapeutics was filed on November 10, 2025 so you should expect the next rating to be made available sometime around November 10, 2026.

While ratings are subjective and will change, the latest Aldeyra Therapeutics (ALDX) rating was a reiterated with a price target of $9.00 to $9.00. The current price Aldeyra Therapeutics (ALDX) is trading at is $5.23, which is out of the analyst’s predicted range.